UY34775A - Uso de laquinimod en alta dosis para el tratamiento de la esclerosis múltiple - Google Patents
Uso de laquinimod en alta dosis para el tratamiento de la esclerosis múltipleInfo
- Publication number
- UY34775A UY34775A UY0001034775A UY34775A UY34775A UY 34775 A UY34775 A UY 34775A UY 0001034775 A UY0001034775 A UY 0001034775A UY 34775 A UY34775 A UY 34775A UY 34775 A UY34775 A UY 34775A
- Authority
- UY
- Uruguay
- Prior art keywords
- laquinimod
- treatment
- multiple sclerosis
- high dose
- dose
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Se describen métodos para tratar sujeto humano mediante provisión de neuroprotección, para tratar paciente humano afectado por esclerosis múltiple o que presenta un síndrome clínicamente aislado, y para tratar paciente mediante incremento del tiempo hasta progresión de enfermedad confirmada o hasta recaída confirmada, o reduciendo atrofia cerebral , comprendiendo administrar oralmente al paciente o sujeto dosis diaria de aproximadamente 1,2 mg/día de laquinimod o de sal del mismo farmacéuticamente aceptable. También se divulga una unidad de dosificación farmacéutica oral de aproximadamente 1,2 mg de laquinimod o una sal del mismo farmacéuticamente aceptable y vehículo farmacéuticamente aceptable para usar en métodos aquí descritos.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261641389P | 2012-05-02 | 2012-05-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UY34775A true UY34775A (es) | 2013-11-29 |
Family
ID=49514859
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UY0001034775A UY34775A (es) | 2012-05-02 | 2013-04-30 | Uso de laquinimod en alta dosis para el tratamiento de la esclerosis múltiple |
Country Status (21)
| Country | Link |
|---|---|
| US (3) | US20130303569A1 (es) |
| EP (1) | EP2844255A4 (es) |
| JP (2) | JP2015515985A (es) |
| KR (1) | KR20150013658A (es) |
| CN (2) | CN105832733A (es) |
| AR (1) | AR090885A1 (es) |
| AU (1) | AU2013256352A1 (es) |
| BR (1) | BR112014027010A2 (es) |
| CA (1) | CA2870684A1 (es) |
| CL (1) | CL2014002935A1 (es) |
| EA (1) | EA201492010A1 (es) |
| HK (1) | HK1206246A1 (es) |
| IL (1) | IL235337A0 (es) |
| MX (1) | MX2014013039A (es) |
| PE (1) | PE20150161A1 (es) |
| PH (1) | PH12014502447A1 (es) |
| SG (1) | SG11201406594UA (es) |
| TW (2) | TW201804997A (es) |
| UY (1) | UY34775A (es) |
| WO (1) | WO2013166166A1 (es) |
| ZA (1) | ZA201408820B (es) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2766020A4 (en) | 2011-10-12 | 2015-04-01 | Teva Pharma | TREATMENT OF MULTIPLE SCLEROSIS BY COMBINING LAQUINIMOD AND FINGOLIMOD |
| WO2013116657A1 (en) | 2012-02-03 | 2013-08-08 | Teva Pharmaceutical Industries Ltd. | USE OF LAQUINIMOD FOR TREATING CROHN'S DISEASE PATIENTS WHO FAILED FIRST-LINE ANTI-TNFα THERAPY |
| EP2744498A4 (en) | 2012-02-16 | 2014-12-03 | Teva Pharma | N-ETHYL-N-PHENYL-1,2-DIHYDRO-4,5-DI-HYDROXY-1-METHYL-2-OXO-3-CHINOLINE CARBOXAMIDE AND THE PREPARATION AND USE THEREOF |
| US20130259856A1 (en) * | 2012-03-27 | 2013-10-03 | Teva Pharmaceutical Industries, Ltd. | Treatment of multiple sclerosis with combination of laquinimod and dimethyl fumarate |
| TW201400117A (zh) | 2012-06-05 | 2014-01-01 | Teva Pharma | 使用拉喹莫德治療眼發炎疾病 |
| TW201410244A (zh) | 2012-08-13 | 2014-03-16 | Teva Pharma | 用於治療ｇａｂａ媒介之疾病之拉喹莫德（ｌａｑｕｉｎｉｍｏｄ） |
| EP2961406A4 (en) * | 2012-10-12 | 2017-01-04 | Teva Pharmaceutical Industries Ltd. | Laquinimod for reducing thalamic damage in multiple sclerosis |
| US8975279B2 (en) | 2012-11-07 | 2015-03-10 | Teva Pharmaceutical Industries, Ltd. | Amine salts of laquinimod |
| BR112015019564A2 (pt) * | 2013-02-15 | 2017-07-18 | Teva Pharma | tratamento de esclerose múltipla com laquinimod |
| AU2014236232A1 (en) | 2013-03-14 | 2015-11-05 | Teva Pharmaceutical Industries Ltd. | Crystals of laquinimod sodium and improved process for the manufacture thereof |
| AR098924A1 (es) * | 2013-12-23 | 2016-06-22 | Teva Pharma | Tratamiento de la esclerosis múltiple con una combinación de laquinimod y teriflunomida |
| SG11201608674UA (en) * | 2014-04-29 | 2016-11-29 | Teva Pharma | Laquinimod for the treatment of relapsing-remitting multiple sclerosis (rrms) patients with a high disability status |
| WO2017027512A1 (en) * | 2015-08-13 | 2017-02-16 | Teva Pharmaceutical Industries Ltd. | Use of laquinimod to treat traumatic brain injury |
| US20190108912A1 (en) * | 2017-10-05 | 2019-04-11 | Iquity, Inc. | Methods for predicting or detecting disease |
| CA3106772A1 (en) * | 2018-07-20 | 2020-01-23 | Merck Patent Gmbh | A substituted amino-pyrimidine compound for use in a method for treatment and prevention of multiple sclerosis |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6077851A (en) * | 1998-04-27 | 2000-06-20 | Active Biotech Ab | Quinoline derivatives |
| DK1797109T3 (en) * | 2004-09-09 | 2016-04-11 | Yeda Res & Dev | MIXTURES OF POLYPEPTIDES, compositions containing them and methods for their preparation, and uses thereof |
| WO2007146331A1 (en) * | 2006-06-12 | 2007-12-21 | Teva Pharmaceutical Industries, Ltd. | Tannate salt form of polypeptide mixtures, their preparation and use |
| DK2442651T3 (en) * | 2009-06-19 | 2015-09-21 | Teva Pharma | Treatment of multiple sclerosis with laquinimod |
| EP2523668A1 (en) * | 2010-01-13 | 2012-11-21 | Ramot at Tel-Aviv University Ltd | Treatment of multiple sclerosis |
| EP2766020A4 (en) * | 2011-10-12 | 2015-04-01 | Teva Pharma | TREATMENT OF MULTIPLE SCLEROSIS BY COMBINING LAQUINIMOD AND FINGOLIMOD |
| BR112015019564A2 (pt) * | 2013-02-15 | 2017-07-18 | Teva Pharma | tratamento de esclerose múltipla com laquinimod |
-
2013
- 2013-04-29 TW TW106117959A patent/TW201804997A/zh unknown
- 2013-04-29 AR ARP130101459A patent/AR090885A1/es unknown
- 2013-04-29 TW TW102115308A patent/TW201347762A/zh unknown
- 2013-04-30 UY UY0001034775A patent/UY34775A/es not_active Application Discontinuation
- 2013-05-01 PE PE2014001911A patent/PE20150161A1/es not_active Application Discontinuation
- 2013-05-01 CN CN201610240473.8A patent/CN105832733A/zh active Pending
- 2013-05-01 WO PCT/US2013/039090 patent/WO2013166166A1/en active Application Filing
- 2013-05-01 CN CN201380022530.XA patent/CN104284663A/zh active Pending
- 2013-05-01 JP JP2015510436A patent/JP2015515985A/ja not_active Withdrawn
- 2013-05-01 EA EA201492010A patent/EA201492010A1/ru unknown
- 2013-05-01 SG SG11201406594UA patent/SG11201406594UA/en unknown
- 2013-05-01 CA CA2870684A patent/CA2870684A1/en not_active Abandoned
- 2013-05-01 BR BR112014027010A patent/BR112014027010A2/pt not_active IP Right Cessation
- 2013-05-01 AU AU2013256352A patent/AU2013256352A1/en not_active Abandoned
- 2013-05-01 MX MX2014013039A patent/MX2014013039A/es unknown
- 2013-05-01 KR KR1020147033707A patent/KR20150013658A/ko not_active Application Discontinuation
- 2013-05-01 EP EP13784231.6A patent/EP2844255A4/en not_active Withdrawn
- 2013-05-01 US US13/874,537 patent/US20130303569A1/en not_active Abandoned
-
2014
- 2014-10-26 IL IL235337A patent/IL235337A0/en unknown
- 2014-10-29 CL CL2014002935A patent/CL2014002935A1/es unknown
- 2014-10-31 PH PH12014502447A patent/PH12014502447A1/en unknown
- 2014-12-02 ZA ZA2014/08820A patent/ZA201408820B/en unknown
-
2015
- 2015-06-05 US US14/731,971 patent/US20150265592A1/en not_active Abandoned
- 2015-07-16 HK HK15106789.5A patent/HK1206246A1/xx unknown
- 2015-09-15 US US14/854,849 patent/US20160000775A1/en not_active Abandoned
-
2017
- 2017-07-21 JP JP2017141409A patent/JP2017222691A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| PH12014502447A1 (en) | 2015-01-12 |
| PE20150161A1 (es) | 2015-02-22 |
| AU2013256352A1 (en) | 2014-11-27 |
| CA2870684A1 (en) | 2013-11-07 |
| KR20150013658A (ko) | 2015-02-05 |
| JP2015515985A (ja) | 2015-06-04 |
| US20150265592A1 (en) | 2015-09-24 |
| EA201492010A1 (ru) | 2015-06-30 |
| JP2017222691A (ja) | 2017-12-21 |
| IL235337A0 (en) | 2014-12-31 |
| CN104284663A (zh) | 2015-01-14 |
| BR112014027010A2 (pt) | 2017-06-27 |
| CN105832733A (zh) | 2016-08-10 |
| CL2014002935A1 (es) | 2015-03-06 |
| US20160000775A1 (en) | 2016-01-07 |
| EP2844255A1 (en) | 2015-03-11 |
| MX2014013039A (es) | 2015-02-04 |
| EP2844255A4 (en) | 2015-10-14 |
| SG11201406594UA (en) | 2014-11-27 |
| ZA201408820B (en) | 2016-06-29 |
| HK1206246A1 (en) | 2016-01-08 |
| AR090885A1 (es) | 2014-12-10 |
| WO2013166166A1 (en) | 2013-11-07 |
| TW201804997A (zh) | 2018-02-16 |
| TW201347762A (zh) | 2013-12-01 |
| US20130303569A1 (en) | 2013-11-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY34775A (es) | Uso de laquinimod en alta dosis para el tratamiento de la esclerosis múltiple | |
| CY1124729T1 (el) | Φαρμακοτεχνικες μορφες του ενζαλουταμιδιου | |
| CL2015000942A1 (es) | Compuestos de benceno sustituido. | |
| PH12019500176A1 (en) | Heterocyclic compounds and ther uses | |
| CL2015000829A1 (es) | Inhibidores de histona desmetilasas | |
| CO2017004525A2 (es) | Dihidropirrolopiridinas inhibidoras de ror-gamma | |
| CL2016002027A1 (es) | Ciclopropilamina como inhibidor de la lsd1 | |
| CR20150472A (es) | USO DE DERIVADOS DE PIRAZOLOPIRIMIDINA PARA EL TRATAMIENTO DE TRANSTORNOS RELACIONADOS CON LA PI3Kd | |
| DOP2015000304A (es) | Inhibidores cristalinos de bromodominios | |
| UA116648C2 (uk) | Фумарати як проліки та їх застосування при лікуванні різних захворювань | |
| EA201692301A1 (ru) | Производные бороновой кислоты и их терапевтическое применение | |
| CL2016001895A1 (es) | Compuestos | |
| MX365939B (es) | Moduladores del transporte nuclear y usos de los mismos. | |
| CL2016002072A1 (es) | 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer | |
| UY34750A (es) | ?compuestos para el tratamiento del hiv, composiciones,métodos de preparación, intermediarios y métodos terapéuticos?. | |
| UY34220A (es) | Indazoles, composiciones farmacéuticas y uso de los mismos | |
| UY34278A (es) | Derivados novedosos de oxazina y su uso en el tratamiento de enfermedades | |
| UY34545A (es) | Novedosas dihidropirimidinoisoquinolinonas y composiciones farmacéuticas de las mismas para el tratamiento de trastornos inflamatorios. | |
| ECSP16008797A (es) | Derivados de heterobicicloaril como inhibidores rorc2 y métodos de uso de los mismos | |
| CL2015002897A1 (es) | Inhibidores de bace1 | |
| GB201209587D0 (en) | Therapeutic compounds | |
| ECSP14011792A (es) | Inhibidores de iap | |
| EA032271B9 (ru) | Вещества, фармацевтическая композиция и методы применения при лечении воспалительных заболеваний | |
| DOP2016000297A (es) | Composiciones farmacéuticas útiles para tratar enfermedades infecciosas | |
| UY34931A (es) | ?formulación compuesta para administración oral que comprende metformina y rosuvastatina?. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 109 | Application deemed to be withdrawn |
Effective date: 20210526 |